News Archives - Page 335 of 721

FridayDec 10, 2021 1:09 pm

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Marks Next Step in Global Expansion with Launch of Its E-Commerce Platform in the UK

PlantX is celebrating the expansion of its e-commerce platform to the United Kingdom The platform will offer a wide array of plant-based products, indoor plants, and educational resources The UK is the leading market for plant-based alternatives in Europe and has in the recent past witnessed changes that align perfectly with PlantX’s recent move The launch of the site fulfills the company’s mission and is a step in the right direction for the PlantX In line with its mission of bringing more plant-based options to as many people as possible, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has announced…

FridayDec 10, 2021 12:55 pm

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Discusses Psychedelics Research, Life Sciences Focus, at Key Industry Conferences

MINDCURE President and CEO Kelsey Ramsden will participate in, and has already attended multiple industry conferences throughout December Participation in #CanndoraConnect: Women in Psychedelics Conference focused on exploring job opportunities in psychedelics Company remains focused on promoting healing and improving mental health via digital therapeutics technology and psychedelic compounds research Company reports that 971 million people worldwide suffer from a mental disorder. As of 2019, MINDCURE calculates that 12,472 registered mental health facilities treatment facilities could benefit from the company’s proprietary digital therapeutics technology, iSTRYM The global digital therapeutics market is valued at $3.4 billion and is projected to reach…

FridayDec 10, 2021 10:20 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Totaling Over $160 Billion

Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s patented DehydraTECH(TM) to improve drug delivery processes for multiple indications Research will continue into the use of DehydraTECH-CBD for high blood pressure, as well as the technology’s potential for oral nicotine delivery Diabetes, rheumatoid disease, Alzheimer’s Disease, and estrogen delivery, are some of the multiple indications that drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX) is planning to target with its research and development programs next year. The markets targeted provide multiple opportunities for success…

FridayDec 10, 2021 9:42 am

SPYR Inc. (SPYR) Is ‘One to Watch’

Applied Magix is currently shipping five products to customers The company plans to add new products to its offerings in 2022 Applied Magix is positioned to take advantage of unmet demand for Apple-compatible smart home and connected car products The global smart home market is forecast to hit more than $187 billion in revenue by 2025, marking a CAGR of 15.75 percent from 2021 The company operates in rapidly growing markets Both SPYR and its Applied MagiX subsidiary have experienced management teams in place SPYR (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its Applied MagiX Inc.…

FridayDec 10, 2021 9:31 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin

The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybin In addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nausea Mydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s NASDAQ listing efforts, bringing decades of experience in biotech development and licensing and strategic advancements Company intends to uplist to NASDAQ in Q1 2022 Improving delivery control and shelf stabilization of psilocybin’s active metabolite psilocin, two critical aspects for use in medical settings, is the…

ThursdayDec 09, 2021 2:15 pm

FingerMotion Inc. (FNGR) Research Agreement with Munich Re Sets Stage for Predictive Insurance Analysis Growth

Rich communication services (“RCS”) provider and big data analysis solutions developer FingerMotion has announced an agreement with Munich Re to form a collaborative research alliance to benefit life and health insurance risk evaluation FingerMotion focuses its SMS, MMS, and big data products on China’s huge high-end phone consumer market The company’s most recent quarterly report noted a 25 percent YOY quarterly growth in revenues attributed to SMS and MMS services The Munich Re agreement follows FingerMotion’s contract earlier this year with Pacific Life Reinsurance to provide big data analytical services for Pacific Life’s insurance operations in China Communications and big…

ThursdayDec 09, 2021 1:54 pm

Flora Growth Corp. (NASDAQ: FLGC) Launches European and Mexican Exports of CBD Skincare Brands

Colombian cannabis cultivator and international wellness product builder Flora Growth Corp. is building a global pipeline for its wide array of branded CBD and medicinal cannabis products The company recently announced that it has begun fulfilling the first orders for its Mind Naturals and Awe CBD skincare brands with exports to Spain and Mexico outlets this month Flora Growth cultivates cannabis at its 100-hectare (247-acre) property in central Colombia Flora also has a GMP certified 16,000-square-foot manufacturing facility in Bogota that produces nearly 200 products for the CBD derivatives and medical cannabis markets Cannabis cultivator and worldwide cannabidiol (“CBD”) brand…

ThursdayDec 09, 2021 1:34 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation

Tryp just announced FDA confirmation for its IND application filed in November 2021 The confirmation allows the company to proceed with its Phase 2a study on the effectiveness of psilocybin-assisted therapy among patients with fibromyalgia This clinical study will be one of the first to evaluate synthetic psilocybin for fibromyalgia in a Phase 2 study It is set to commence in 2022 and will involve 20 fibromyalgia patients Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/C20cT).…

ThursdayDec 09, 2021 1:24 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Fund, Support First-Ever Psychedelic Treatment Clinic at Manhattan Hospital

Company receives grant to fund clinic for marginalized, underserved NYC communities New clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the service Program’s clinicians will receive specialized training Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital (https://ibn.fm/zyerA). Part of Northwell Health, the largest healthcare system in New York State, Lenox Hill Hospital serves marginalized and underserved communities on the Upper East…

WednesdayDec 08, 2021 1:50 pm

American Cannabis Partners’ Strict Adherence to Jamaican Cultivation Techniques Results in Much Sought-After Flower

Jamaican cannabis has benefitted from burgeoning global demand in 2021, with the regulator issuing 42 export licenses American Cannabis Partners has sought to capitalize on growing demand for Jamaican cannabis through a strict adherence to Jamaican cultivation techniques given its close links to the nation US cannabis cultivators are gradually increasing their focus on product differentiation to gain market share within the rapidly growing sector For Jamaican cannabis cultivators, business is booming. The nation’s industry regulator, the Cannabis Licensing Authority (“CLA”), recently revealed that it had witnessed a dramatic uptick in demand for Jamaican ‘ganja’ on the global market, having…

Site Search

Company Search

Category: News